Quest Diagnostics, Inc. (DGX) Tops Q1 EPS by 6c; Raises FY12 Outlook
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $237.14 -0.94%
Revenue Growth %: +7.8%
Financial Fact:
Less: Net income attributable to noncontrolling interests: 13M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +7.8%
Financial Fact:
Less: Net income attributable to noncontrolling interests: 13M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Quest Diagnostics, Inc. (NYSE: DGX) reported Q1 EPS of $1.07, $0.06 better than the analyst estimate of $1.01. Revenue for the quarter came in at $1.94 billion versus the consensus estimate of $1.88 billion.
Raises its FY12 EPS guidance to $4.45-$4.60, which compares to the Street estimate of $4.54. The company previously guided to $4.40-$4.55.
For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.
Raises its FY12 EPS guidance to $4.45-$4.60, which compares to the Street estimate of $4.54. The company previously guided to $4.40-$4.55.
For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
